Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818480 · ClinicalTrials.gov registry record · Phase 2
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
A Phase 2 study of Prostate Cancer and Melanoma, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT00818480 is a Phase 2 study of Prostate Cancer and Melanoma that has completed, run by Astellas Pharma. The registered enrollment target is 10 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00818480, a Phase 2 study of Prostate Cancer and Melanoma, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the previous study.
Conditions Studied
Interventions
- DRUG YM155
Study Locations (3)
Texas
- Institute for Drug Development - San Antonio
- South Texas Accelerated - San Antonio
Utah
- Huntsman Cancer Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00818480
The ClinicalTrials.gov registry entry for NCT00818480 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which YM155 is the first listed.
NCT00818480 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT00818480 about?
NCT00818480 is a clinical study titled "An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155". This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the previous study.
What is the current status of trial NCT00818480?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-02. Estimated completion is 2012-08.
What conditions does trial NCT00818480 study?
This clinical trial studies the following conditions: Prostate Cancer, Melanoma, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00818480?
The interventions under investigation include: YM155 (DRUG).
Who is sponsoring clinical trial NCT00818480?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00818480 being conducted?
This trial has 3 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.